Clinical Trial

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Name: DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer — clinical trial record (NCT07249372)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-18.

Trial Details

NCT Number	NCT07249372
Lead Sponsor	NYU Langone Health
Conditions	Non Small Cell Lung Cancer
Enrollment	37 participants
Start Date	2026-01-14
Primary Completion	2027-10-31 (estimated)
Study Completion	2028-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-26